首頁
Shanghai Junshi Biosciences

7月 2026Shanghai Junshi Biosciences的市場佔有率分析

We aim to develop first-in-class and best-in-class macromolecular drugs through original innovation. We have established a globally integrated R&D process with several R&D centers worldwide. We have built up whole-industry-chain technology platforms and mechanism of innovation for macromolecular drugs covering from early discovery to industrialization.

健康 > 生物技術和製藥

域名junshipharma.com

成立年份2012

僱員1001 - 5000

年度營收$200M - $500M

Shanghai Junshi Biosciences

Shanghai Junshi Biosciences（包含公司地區）

junshipharma.com

查看更多網站流量與參與度資訊

Shanghai Junshi Biosciences截至 7月 2026 的總收入為 200M - 500M

Shanghai Junshi Biosciences 熱門網域產生的總收入

Shanghai Junshi Biosciences 熱門網域 3 年內的總收入

Shanghai Junshi Biosciences 熱門網域的總收入

junshipharma.com200M - 500M

透過銷售情報查看更多內容

Shanghai Junshi Biosciences的熱門網域總造訪量

了解Shanghai Junshi Biosciences市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

junshipharma.com6.1K

透過銷售情報查看更多內容

Shanghai Junshi Biosciences的熱門網域平均造訪時長

分析Shanghai Junshi Biosciences參與度指標。

過去 3 個月平均造訪時長

子公司細目

junshipharma.com00:02:13

透過銷售情報查看更多內容

Shanghai Junshi Biosciences的熱門網域平均頁面瀏覽量

了解Shanghai Junshi Biosciences如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

junshipharma.com2.81

透過銷售情報查看更多內容

Shanghai Junshi Biosciences按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Shanghai Junshi Biosciences

这些是Shanghai Junshi Biosciences顶级域名使用的行业网站技术

內容管理系統 (3)

WordPress

行動裝置 (2)

Meta Viewport

多語言 (2)

Multilingual Support

小工具 (2)

Yoast SEO

更多技術

4

檢視所有

新聞與訊號來自Shanghai Junshi Biosciences

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Antengene Corporation partners with Junshipharma.Antengene enters into collaboration with Junshi Biosciences to evaluate ATG-037 and JS207 in solid tumours.

新聞Junshipharma partnered with Leo Pharma Inc. on Jan 20th '25.SHANGHAI, China I January 20, 2025 I Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced a distribution and marketing partnership with LEO Pharma for toripalimab in Europe.

新聞Junshipharma launches TORCHLIGHT Phase 3 study in Nature Medicine.Shanghai Junshi Biosciences, a biopharmaceutical frontrunner, has announced the findings of the TORCHLIGHT Phase 3 study in Nature Medicine, unveiling the effectiveness and safety of toripalimab in tandem with nab-paclitaxel for patients suffering from advanced triple-negative breast cancer (TNBC).